Biomedical Research Center
251 Bayview Boulevard
Suite 200, Room 04A521
Baltimore, MD 21224
Scientific Director: Antonello Bonci, M.D.
Deputy Scientific Director: Amy Hauck Newman, Ph.D.
Chief of Staff: Michelle Leff, M.D., M.B.A. (CAPT, USPHS)
Regulatory Affairs Officer: Leslie Premo (MPP, MS)
The Office of the Scientific Director provides scientific, program, and administrative leadership for the Division of Intramural Research; promotes an environment conducive to productive research; and coordinates activities, establishes priorities, and analyzes and evaluates progress.
Training programs at the NIDA Intramural Research Program are designed to train the next generation of leaders in basic and clinical drug abuse research. NIDA provides research training opportunities for high school, undergraduate, postbaccalaureate, graduate, medical, and postdoctoral students.
Director: Stephen Heishman, Ph.D.
The DOC is charged with the task of building a comprehensive diversity program within the NIH/NIDA IRP. Its mission is thus to recruit high school students, post-baccalaureate students, and postdoctoral students, with the long-term goal of developing and recruiting tenure track scientists from under-represented populations in order to increase diversity in biomedical science. The Committee’s tasks also include developing community outreach programs that will benefit the diverse populations living in Baltimore. These programs will aim to provide better community awareness and understanding of drug abuse research programs at the NIDA IRP.
Associate Director: Michelle Jobes, Ph.D.
The Animal Care and Use Program of the Office of the Director is responsible for oversight of animal care and use at the Intramural Research Program of the National Institute on Drug Abuse and provides animal research support services to intramural investigators. The Program also provides advice, guidance, and consultative services to scientific and administrative staff of the Institute.
The main goal of the DDRU is to collect, analyze and disseminate the most up-to-date information about the pharmacology and toxicology of newly-emerging designer drugs of abuse, more formally known as new psychoactive substances (NPS). NPS include synthetic drugs which mimic the effects of stimulants (e.g., “bath salts”), cannabinoids (e.g., “spice”), hallucinogens (e.g., “NBOMes”) and opioids (e.g., fentanyl analogs). These substances are specifically engineered to circumvent drug control laws and are often misused as a means to avoid detection of drug use.
Chief: Michael H. Baumann, Ph.D.
Topics of investigation include:
- Pharmacology of newly-emerging designer drugs of abuse, such as “bath salts” stimulants and “K2/Spice” cannabinoids
- Structure-activity relationships for ligands interacting at monoamine transporter proteins
- Mechanisms underlying neurotoxic effects of stimulant drugs of abuse